Skip to main content
. 2022 Jan 11;2022:1040693. doi: 10.1155/2022/1040693

Table 2.

Pharmacokinetic assessment of synthesized drugs 3(a–e) and 5(a–e).

Compound M.Wt ≤ 500 HBA ≤ 10 HBD ≤ 5 LogP ≤ 5 LogS (mol/L) ≤ −4 PSA ≤ 140 (A2) Vol (A3) Drug likeness score > 0 RO5
3a 313.10 5 2 2.54 -2.65 75.69 301.07 0.16 Yes
3b 313.10 5 2 2.51 -2.78 75.69 300.99 0.49 Yes
3c 329.09 6 3 2.76 -3.23 92.24 312.25 0.74 Yes
3d 329.09 6 3 1.96 -2.40 91.17 313.72 0.60 Yes
3e 329.09 6 3 2.10 -2.62 93.31 311.77 -0.08 Yes
5a 323.12 4 1 3.52 -3.67 57.48 334.19 -0.60 Yes
5b 339.11 5 2 2.96 -3.33 75.09 344.74 -0.05 Yes
5c 355.11 6 3 2.72 -3.11 91.64 355.34 -0.08 Yes
5d 357.08 4 1 4.12 -4.73 57.48 351.39 -0.04 Yes
5e 341.13 5 2 2.82 -3.30 75.09 336.60 -0.01 Yes
Kojic acid 142.03 4 2 -1.07 -0.08 56.19 148.32 -1.04 Yes
Arbutin 272.09 7 5 -1.14 -0.96 97.71 228.69 -1.04 Yes

M.Wt: molecular weight; HBA: number of hydrogen bond acceptor; HBD: number of hydrogen bond donor, LogP: partition coefficient; LogS: lipophilicity of water; PSA: total polar surface area; RO5: Lipinski's rule of 5.